These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25611784)

  • 1. Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.
    Harada H; Harada Y
    Cancer Sci; 2015 Apr; 106(4):329-36. PubMed ID: 25611784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [MDS: Recent progress in molecular pathogenesis and clinical aspects].
    Harada H
    Rinsho Ketsueki; 2017; 58(10):1941-1950. PubMed ID: 28978836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.
    Haider M; Duncavage EJ; Afaneh KF; Bejar R; List AF
    Am Soc Clin Oncol Educ Book; 2017; 37():480-494. PubMed ID: 28561687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
    Gill H; Leung AY; Kwong YL
    Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
    Zhang L; Padron E; Lancet J
    Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome.
    Chen CY; Lin LI; Tang JL; Ko BS; Tsay W; Chou WC; Yao M; Wu SJ; Tseng MH; Tien HF
    Br J Haematol; 2007 Nov; 139(3):405-14. PubMed ID: 17910630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
    Itzykson R; Kosmider O; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
    Boultwood J; Dolatshad H; Varanasi SS; Yip BH; Pellagatti A
    Adv Biol Regul; 2014 Jan; 54():153-61. PubMed ID: 24080589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic Syndromes: Updates and Nuances.
    Dao KT
    Med Clin North Am; 2017 Mar; 101(2):333-350. PubMed ID: 28189174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
    Nakajima H
    Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
    Harada Y; Harada H
    J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.
    Zahid MF; Patnaik MM; Gangat N; Hashmi SK; Rizzieri DA
    Eur J Haematol; 2016 Oct; 97(4):313-20. PubMed ID: 27147278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
    Harada H; Harada Y; Kimura A
    Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic basis of myelodysplastic syndromes.
    Ogawa S
    Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(3):107-121. PubMed ID: 32161209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
    Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
    Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.